5 results on '"Yokozaki M"'
Number of results to display per page
Search Results
2. [Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2012].
- Author
-
Yamaguchi K, Ishii Y, Tateda K, Iwata M, Watanabe N, Shinagawa M, Kayaba H, Kimura M, Suwabe A, Kaku M, Abe Y, Kanemitsu K, Taniguchi N, Murakami M, Maesaki S, Kawamura T, Nomura F, Watanabe M, Kanno H, Horiuchi H, Tazawa Y, Kondo S, Misawa S, Takemura H, Nakashima H, Matsuto T, Fujimoto Y, Ishigo S, Gotoh H, Watanabe O, Yagi T, Shimaoka N, Mikamo H, Yamagishi Y, Fujita N, Komori T, Ichiyama S, Kawano S, Nakayama A, Nakamura F, Kohno H, Fukuda S, Kusano N, Nose M, Yokozaki M, Onodera M, Murao K, Negayama K, Nishimiya T, Miyamoto H, Matsunaga A, Yoshimura H, Kohno S, Yanagihara K, and Hiramatsu K
- Subjects
- Drug Resistance, Bacterial, Humans, Meropenem, Microbial Sensitivity Tests, Anti-Bacterial Agents pharmacology, Bacteria drug effects, Thienamycins pharmacology
- Abstract
The nationwide surveillance of antibacterial susceptibility to meropenem (MEPM) and other parenteral antibiotics against clinical isolates during 2012 in Japan was conducted. A total of 2985 strains including 955 strains of Gram-positive bacteria, 1782 strains of Gram-negative bacteria, and 248 strains of anaerobic bacteria obtained from 31 medical institutions were examined. The results were as follows; 1. MEPM was more active than the other carbapenem antibiotics tested against Gram-negative bacteria, especially against enterobacteriaceae and Haemophilus influenzae. MEPM was also active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus (MRSA). 2. Of all species tested, there were no species, which MIC90 of MEPM was more than 4-fold higher than those in our previous studies in 2009 or 2006. Therefore, the tendency to increase in antimicrobial resistance rates was not observed. 3. MEPM resistance against Pseudomonas aeruginosa was 17.8% (56/315 strains). Compared to our previous results, it was the lowest than that in 2006 and 2009. 4. Carbapenem-resistant Klebsiella pneumoniae, and multi-drug-resistant Acinetobacter species, which emerged in worldwide, were not observed. 5. The proportion of extended-spectrum beta-lactamase (ESBL) strains was 6.2% (59/951 strains) in enterobacteriaceae, which increased compared with that of our previous studies in 2009 or before. Whereas, the proportion of metallo-beta-lactamase strains was 1.6% (5/315 strains) in P. aeruginosa, which was stable. In conclusion, the results from this surveillance suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem for serious infections treatment at present, 17 years passed after available for commercial use in Japan.
- Published
- 2014
3. Meropenem resistance in imipenem-susceptible meropenem-resistant Klebsiella pneumoniae isolates not detected by rapid automated testing systems.
- Author
-
Harino T, Kayama S, Kuwahara R, Kashiyama S, Shigemoto N, Onodera M, Yokozaki M, Ohge H, and Sugai M
- Subjects
- Humans, Japan, Klebsiella pneumoniae isolation & purification, Meropenem, Microbial Sensitivity Tests methods, Anti-Bacterial Agents pharmacology, Diagnostic Errors, Imipenem pharmacology, Klebsiella Infections microbiology, Klebsiella pneumoniae drug effects, Thienamycins pharmacology, beta-Lactam Resistance
- Abstract
Klebsiella pneumoniae showing high resistance to all β-lactams except imipenem, designated as ISMRK (imipenem-susceptible meropenem-resistant Klebsiella) is emerging in Japan. The carbapenem resistance of ISMRK cannot be screened by the Vitek and the RAISUS rapid automated susceptibility test systems, which may lead to inappropriate antimicrobial therapy, resulting in compromised patient outcomes.
- Published
- 2013
- Full Text
- View/download PDF
4. Emergence in Japan of an imipenem-susceptible, meropenem-resistant Klebsiella pneumoniae carrying blaIMP-6.
- Author
-
Shigemoto N, Kuwahara R, Kayama S, Shimizu W, Onodera M, Yokozaki M, Hisatsune J, Kato F, Ohge H, and Sugai M
- Subjects
- Aged, 80 and over, Conjugation, Genetic, Female, Gene Transfer, Horizontal, Humans, Japan, Klebsiella pneumoniae drug effects, Klebsiella pneumoniae genetics, Klebsiella pneumoniae isolation & purification, Male, Meropenem, Plasmids analysis, Anti-Bacterial Agents pharmacology, Imipenem pharmacology, Klebsiella Infections microbiology, Klebsiella pneumoniae enzymology, Thienamycins pharmacology, beta-Lactam Resistance, beta-Lactamases metabolism
- Abstract
We identified 5 Klebsiella pneumoniae isolates showing high resistance to β-lactams except imipenem and designated them ISMRK (imipenem-susceptible but meropenem-resistant Klebsiella). They carried the bla(IMP-6) and bla(CTX-M-2) on a self-transmissible plasmid. ISMRK may be falsely categorized as susceptible to carbapenems if imipenem is used to screen carbapenem resistance., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
5. [Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2009].
- Author
-
Yamaguchi K, Ishii Y, Iwata M, Watanabe N, Shinagawa M, Yasujima M, Suwabe A, Kuroda M, Kaku M, Kitagawa M, Kanemitsu K, Imafuku Y, Murakami M, Yomodu S, Taniguchi N, Yamada T, Nomura F, Kanno H, Maesaki S, Hashikita G, Kondo S, Misawa S, Horiuchi H, Tazawa Y, Nakashima H, Takemura H, Okada M, Horikawa Y, Maekawa M, Nagura O, Yagi T, Baba H, Ishigo S, Fujita N, Komori T, Ichiyama S, Yamanaka K, Murata Y, Matsuo S, Kohno H, Kawano S, Kinoshita S, Taminato T, Negayama K, Murase M, Miyamoto H, Kusano N, Nose M, Yokozaki M, Itaha H, Matsunaga A, Yoshimura H, Kohno S, Yanagihara K, Matsuda J, Saikawa T, and Hiramatsu K
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Dosage Forms, Drug Resistance, Bacterial, Humans, Infant, Infant, Newborn, Japan, Meropenem, Middle Aged, Respiratory System microbiology, Time Factors, Urine microbiology, Young Adult, Anti-Bacterial Agents pharmacology, Bacteria, Anaerobic drug effects, Bacteria, Anaerobic isolation & purification, Bacterial Infections microbiology, Gram-Negative Bacteria drug effects, Gram-Negative Bacteria isolation & purification, Gram-Positive Bacteria drug effects, Gram-Positive Bacteria isolation & purification, Thienamycins pharmacology
- Abstract
The antibacterial activity of meropenem (MEPM) and other parenteral antibiotics against clinical isolates of 2655 strains including 810 strains of Gram-positive bacteria, 1635 strains of Gram-negative bacteria, and 210 strains of anaerobic bacteria obtained from 30 medical institutions during 2009 was examined. The results were as follows; (1) MEPM was more active than the other carbapenem antibiotics tested against Gram-negative bacteria, especially against enterobacteriaceae and Haemophilus influenzae. MEPM was also active against most of the species tested in Gram-positive and anaerobic bacteria, except for multidrug resistant strains including methicillin-resistant Staphylococcus aureus (MRSA). (2) MEPM maintained potent and stable antibacterial activity against Pseudomonas aeruginosa. The proportion of MEPM-resistant strains to ciprofloxacin-resistant strains or imipenem-resistant strains were 53.1% and 58.0% respectively. (3) The proportion of extended-spectrum beta-lactamase (ESBL) strains was 3.1% (26 strains) in enterobacteriaceae. And the proportion of metallo-beta-lactamase strains was 2.0% (6 strains) in P. aeruginosa. (4) Of all species tested, there were no species except for Bacteroides fragilis group, which MIC90 of MEPM was more than 4-fold higher than those in our previous study. Therefore, there is almost no significant decrease in susceptibility of clinical isolates to meropenem. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem for serious infections treatment at present, 14 years passed after available for commercial use in Japan.
- Published
- 2011
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.